← Human Trials & Peer-Reviewed Studies
Magnesium Sulfate and Hematoma Expansion: An Ancillary Analysis of the FAST-MAG Randomized Trial.
Plain-language guide to PMID 35380053 (2022): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 35380053
- Journal
- Stroke
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Naidech AM et al. (11 authors)
- DOI
- 10.1161/STROKEAHA.121.037999
- Registered trial
- NCT00059332
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The researchers used the same method to compare neurological deficit severity (National Institutes of Health Stroke Scale) and global disability (modified Rankin Scale) at 3 months.
Why It Was Studied
Intracerebral hemorrhage (ICH) is the deadliest form of stroke.
In this ancillary analysis, the researchers assessed the effect of magnesium sulfate treatment upon HE in patients with acute ICH.
Who Took Part
PubMed tags the participants as both men and women.
CT was not required prior to enrollment, and several hundred patients with acute ICH were enrolled.
The researchers compared HE among patients allocated to intravenous magnesium sulfate or placebo with a Mann-Whitney U.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
The researchers retrospectively analyzed data that were prospectively collected in the FAST-MAG study.
What Was Measured
In this ancillary analysis, the researchers assessed the effect of magnesium sulfate treatment upon HE in patients with acute ICH.
Topics PubMed links to this paper include Cerebral Hemorrhage, Hematoma, Magnesium, Magnesium Sulfate, Stroke and United States.
Author keywords: hypertension and serum.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (Stroke), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.